Skip to main content
Bonesupport Holding logo

Bonesupport Holding — Investor Relations & Filings

Ticker · BONEX ISIN · SE0009858152 LEI · 549300COLY053IGTLD63 ST Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2018-08-24 Regulatory Filings
Country SE Sweden
Listing ST BONEX

About Bonesupport Holding

https://www.bonesupport.com/en-eu/

Bonesupport Holding is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes. Its core product platform, CERAMENT®, is an innovative range of osteoconductive and drug-eluting products designed to heal bone defects. A key characteristic of CERAMENT® is its ability to remodel into the patient's own host bone, typically within six to twelve months. The products are used to treat bone voids and defects arising from trauma, infection, disease, or related surgical procedures. The radiopaque nature of the material allows for visualization during and after surgery.

Recent filings

Filing Released Lang Actions
Save the date: BONESUPPORT Capital Markets Days to be held in Stockholm and London
Regulatory Filings Classification · 1% confidence The document is a short announcement dated August 24, 2018, inviting analysts and investors to upcoming 'Capital Markets Days' in Stockholm and London in September 2018. It provides dates, times, speaker information, and contact details. It is not a full financial report (like 10-K or IR), nor is it a formal earnings release (ER). Since it is an announcement inviting investors to an event where strategy and performance will likely be discussed, it most closely aligns with an Investor Presentation (IP) announcement or a general corporate update. However, given the context of inviting investors to a specific event focused on the company's business and strategy (Capital Markets Day), it functions as a precursor or announcement for investor engagement materials. Since there is no specific code for 'Capital Markets Day Announcement,' and it is an invitation to an investor-focused event, it is best classified as an Investor Presentation (IP) announcement, or potentially a Regulatory Filing (RNS) if it were purely administrative. Given the content is highly investor-focused, IP is a strong candidate, but because it is an *announcement* of an event rather than the presentation itself, and it is short, it could also be RNS. Reviewing the definitions, it is not a standard 'Report Publication Announcement' (RPA) as it announces an event, not a report. Since it is a specific corporate communication aimed at investors about future strategy/performance updates, and it is not a formal filing type, I will lean towards the most relevant investor-focused category, IP, recognizing it is an announcement of an event that will contain IP-like material. However, if we strictly follow the 'MENU VS MEAL' rule, this is an announcement, not the presentation itself. Since it doesn't fit perfectly into the other specific categories, RNS (Regulatory Filings/Miscellaneous) is the safest fallback for a short, non-standard announcement. Given the high investor focus, I will select IP as the intended category for the *subject matter*, but acknowledge its format is an announcement. Let's re-evaluate: It is an invitation to a CMD. CMDs often lead to Investor Presentations. If the document were longer and contained the presentation slides, it would be IP. As a short announcement of the event, it is a general corporate communication. I will classify it as RNS as the best fit for a short, non-standard corporate announcement that doesn't fit the other specific categories like ER, DIV, or CAP.
2018-08-24 English
Save the date: BONESUPPORT Kapitalmarknadsdagar i Stockholm och London
Report Publication Announcement Classification · 1% confidence The document is a press release dated August 24, 2018, announcing upcoming 'Kapitalmarknadsdagar' (Capital Markets Days) in Stockholm and London scheduled for September 19 and 20, 2018. It invites analysts and investors and states that a formal invitation with the agenda will be published later. Since this document is an announcement about a future event where presentations will be given, and it is not the presentation itself, nor is it a formal regulatory filing like a 10-K or ER, it best fits the category of an Investor Presentation (IP) announcement or a general Regulatory Filing (RNS). Given the context of inviting investors to a specific event focused on company strategy and financials (Capital Markets Days), 'Investor Presentation' (IP) is a strong candidate, although the document itself is an announcement *of* the event, not the presentation slides. However, since the document is short (3140 chars) and primarily serves to inform stakeholders about an upcoming investor-focused event, it is most closely related to investor communications. If the document were the actual presentation slides, IP would be certain. As it is an announcement of an event where presentations will occur, and it doesn't fit other specific categories like ER, DIV, or DIRS, we must choose between RNS (general regulatory) or IP (investor-focused event announcement). Given the specific nature of Capital Markets Days, IP is more descriptive than the generic RNS. However, following Rule 2 (Menu vs Meal), since this is an announcement about future presentations rather than the presentation itself, and it is not a standard regulatory filing, RNS (Regulatory Filings - fallback) is often used for such non-standard announcements, or we could consider it a precursor to an Investor Presentation. Since the event is explicitly about capital markets/investors, and the content is highly relevant to investors, I will classify it as an Investor Presentation (IP), acknowledging it is the announcement thereof, as it is more specific than RNS.
2018-08-24 Swedish
BONESUPPORT - CERAMENT® G Approved by Health Canada
Regulatory Filings Classification · 1% confidence The document announces a specific regulatory approval ('CERAMENT® G Approved by Health Canada') and provides details about the product, ongoing clinical trials (FORTIFY trial), and future US filing plans (PMA). It is a focused announcement about a product milestone and regulatory event, rather than a comprehensive annual report (10-K), a quarterly report (IR), or a general earnings release (ER). Since it is a specific, material announcement that doesn't fit the definitions for M&A, Capital Change, Dividend, or Director Dealing, it falls best under the general 'Regulatory Filings' category (RNS) as a significant regulatory update, or potentially a Capital/Financing Update (CAP) if the approval was tied to immediate commercialization funding, but RNS is the most appropriate catch-all for specific regulatory news not covered elsewhere. Given the options, this is a specific regulatory news release. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal financial report (10-K, IR). It is a specific regulatory event announcement, making RNS the best fit as a general regulatory filing/announcement.
2018-08-16 English
BONESUPPORT - CERAMENT® G är godkänt av Health Canada
Regulatory Filings Classification · 1% confidence The document is a press release dated August 16, 2018, announcing that BONESUPPORT's product, CERAMENT G, has received approval from Health Canada. It details the product, ongoing clinical trials (FORTIFY), future US application plans, and includes standard boilerplate information about the company and contact details. The final paragraph explicitly states: "Denna information är sådan information som BONESUPPORT HOLDING AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is such information that BONESUPPORT HOLDING AB (publ) is obliged to disclose pursuant to the EU's Market Abuse Regulation.) This structure—a formal announcement of a material event under MAR obligations—is characteristic of a general regulatory announcement, which fits best under the 'Regulatory Filings' (RNS) category, as it is not a specific financial report (10-K, IR, ER) or a management/board change (MANG). Given its nature as a mandatory disclosure under EU regulation, RNS is the most appropriate classification.
2018-08-16 Swedish
BONESUPPORT Signs Agreement with MTF Biologics to Expand US Product Offering
Regulatory Filings Classification · 1% confidence The document is a press release announcing a strategic agreement between BONESUPPORT and MTF Biologics regarding the expansion of BONESUPPORT's US product offering. It details a business development/partnership, not a mandatory regulatory filing like a 10-K, an earnings report (ER), or a formal dividend notice (DIV). It is a general corporate announcement regarding business operations and strategy. Since it does not fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), and it is a formal announcement, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for significant, non-standard corporate news releases that are often filed with exchanges.
2018-08-02 English
BONESUPPORT tecknar avtal med MTF Biologics för att utöka produktutbudet i USA
Regulatory Filings Classification · 1% confidence The document is a press release dated August 2, 2018, announcing a strategic agreement between BONESUPPORT and MTF Biologics to expand BONESUPPORT's product offering in the USA. It details the nature of the agreement (licensing DBM products) and includes quotes from management. The final paragraph explicitly states: "Denna information är sådan information som BONESUPPORT HOLDING AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is information that BONESUPPORT HOLDING AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.) This structure strongly indicates a regulatory disclosure of material, non-public information, which typically falls under general regulatory announcements or, if it were a specific type like dividend or insider trade, those specific codes. Since this is a strategic business development announcement required for disclosure under MAR, and it doesn't fit perfectly into ER, IR, or CAP (though it has elements of CAP), the most appropriate general category for mandatory regulatory disclosures that aren't standard financial reports (10-K, IR) or specific corporate actions (DIV, DIRS) is Regulatory Filings (RNS). It is not a Report Publication Announcement (RPA) because it is the substantive announcement itself, not just a notice that a report is attached.
2018-08-02 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.